Janux Therapeutics (JANX) call put ratio 1 call to 2.8 puts into data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Janux Therapeutics (JANX) PT Raised to $115 at Stifel
December 3, 2024 8:22 AM ESTStifel analyst Bradley Canino raised the price target on Janux Therapeutics (NASDAQ: JANX) to $115.00 (from $70.00) while maintaining a Buy rating.
The analyst comments "The JANX007 (PSMA-TRACTr) phase 1 update (LINK) leads us to increase our PoS for 2L and 3L mCRPC to 50% and 65%, respectively... More
William Blair on Janux Therapeutics (JANX): 'Exceeding Investor Expectations and Raising the Bar in mCRPC'
December 3, 2024 7:06 AM ESTWilliam Blair analyst Matt Phipps reiterated an Outperform rating on Janux Therapeutics (NASDAQ: JANX).
The analyst comments "On Monday, December 2, Janux disclosed updated clinical results with JANX007, the companys PSMAxCD3 TRACTr bispecific T-cell engager, in patients with heavily pretreated metastatic castrate resistant prostate cancer (mCRPC), demonstrating... More
Janux Therapeutics (JANX) PT Raised to $91 at Leerink Partners
December 3, 2024 6:55 AM ESTLeerink Partners analyst Jeffrey La Rosa raised the price target on Janux Therapeutics (NASDAQ: JANX) to $91.00 (from $79.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: Janux (JANX, OP) delivered with updated Ph 1 dose escalation data for lead candidate JANX007 (masked PSMA x... More
